Gilead Sciences Inc (NASDAQ:GILD) stock is trading higher on Thursday after the company reported better-than-expected ...

BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and ...

Gilead (GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection, ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of HIV research findings at the International ...

Gilead Sciences' Q3 2024 results exceeded expectations, driven by a strong performance of the HIV portfolio. Read why I ...

Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...

Mohit Bansal, an analyst from Wells Fargo, maintained the Buy rating on Gilead Sciences (GILD – Research Report). The associated price ...

Gilead Sciences Inc.’s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings ...

A decade after the HCV boom, Gilead has become quite reliant on its core HIV franchise, responsible for two-third of total ...

Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...

For the first time, the Asia Pacific Chemsex Symposium (APCS) has moved from Taipei to Bangkok, marking a new chapter in its ...